PMID- 23283827
OWN - NLM
STAT- MEDLINE
DCOM- 20130823
LR  - 20221207
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
VI  - 29
IP  - 3
DP  - 2013 Mar
TI  - Sleep apnoea syndrome and 10-year cardiovascular risk in females with type 2 
      diabetes: relationship with insulin secretion and insulin resistance.
PG  - 227-34
LID - 10.1002/dmrr.2387 [doi]
AB  - BACKGROUND: Obstructive sleep apnoea syndrome (OSAS) is a risk factor for type 2 
      diabetes mellitus (T2DM) and promotes cardiovascular events, especially in men. 
      The prevalence of sleep apnoea and its association with microvascular and 
      macrovascular diseases and glycaemic control are poorly documented in T2DM women. 
      METHODS: A total of 305 T2DM women were sleep apnoea diagnosed through 
      (hetero)anamnesis, Epworth's score, oximetry and polysomnography. Sleep apnoea[+] 
      (n = 25) were compared with sleep apnoea[-] (n = 280) regarding cardiovascular 
      risk factors, glucose homeostasis, micro/macrovascular complications and the 
      United Kingdom Prospective Diabetes Study (UKPDS) 10-year risk. RESULTS: Mean (1 
      SD) age was 66 (12) years, diabetes duration 15 (9) years, sleep apnoea 
      prevalence 8.2% and metabolic syndrome 86%. There were no differences in age, 
      diabetes duration, education, smoking and blood pressure between groups. Sleep 
      apnoea[+] had significantly higher values of body mass index, waist, 
      relative/absolute fat, conicity, visceral fat (all p < 0.0001) and lower skeletal 
      muscle (p = 0.0008). The sleep apnoea[+] group was more insulin resistant 
      [homeostasis model assessment (HOMA S): 37 (20)% versus 59 (44)%; p < 0.0001] and 
      had lesser residual insulin secretion (HOMA B x S: 20 (12)% versus 30 (19)%; p = 
      0.0006), increased hyperbolic product loss (p = 0.0442) and poorer glycaemic 
      control (HbA1c 69 (12) versus 62 (13) mmol mol(-1) ; p = 0.0099). All atherogenic 
      dyslipidaemia components and inflammatory markers were worsened in sleep 
      apnoea[+]. Women with sleep apnoea had higher UKPDS risk of CAD: 18 (11)% versus 
      12 (10)% (p = 0.0136). Prevalent micro/macrovascular complications were not 
      different between groups. CONCLUSIONS: Sleep apnoea, a frequent comorbidity of 
      T2DM women, is associated with central fat, atherogenic dyslipidaemia, 
      inflammation, worsening beta-cell function, poorer glycaemic control and coronary 
      artery disease risk. Sleep apnoea may increase residual vascular risk for 
      microvascular and macrovascular events in T2DM women.
CI  - Copyright (c) 2013 John Wiley & Sons, Ltd.
FAU - Hermans, Michel P
AU  - Hermans MP
AD  - Division of Endocrinology and Nutrition, Universite catholique de Louvain, 
      Brussels, Belgium. michel.hermans@diab.ucl.ac.be
FAU - Ahn, Sylvie A
AU  - Ahn SA
FAU - Mahadeb, Yovan P
AU  - Mahadeb YP
FAU - Rousseau, Michel F
AU  - Rousseau MF
LA  - eng
PT  - Journal Article
PL  - England
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Insulin)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Aged
MH  - Cardiovascular Diseases/*etiology
MH  - Cohort Studies
MH  - Diabetes Mellitus, Type 2/*etiology
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Insulin/*metabolism
MH  - Insulin Resistance/physiology
MH  - Insulin Secretion
MH  - Middle Aged
MH  - Risk Factors
MH  - Sleep Apnea Syndromes/*complications
EDAT- 2013/01/04 06:00
MHDA- 2013/08/24 06:00
CRDT- 2013/01/04 06:00
PHST- 2012/03/22 00:00 [received]
PHST- 2012/09/03 00:00 [revised]
PHST- 2012/12/14 00:00 [accepted]
PHST- 2013/01/04 06:00 [entrez]
PHST- 2013/01/04 06:00 [pubmed]
PHST- 2013/08/24 06:00 [medline]
AID - 10.1002/dmrr.2387 [doi]
PST - ppublish
SO  - Diabetes Metab Res Rev. 2013 Mar;29(3):227-34. doi: 10.1002/dmrr.2387.